Poly(ADP-ribose) polymerase 1 (PARP1)

Overview

Poly(ADP-ribose) polymerase 1 (PARP1) is an abundant nuclear enzyme and the cell's principal sensor of single-strand DNA breaks. Its zinc-finger domains bind the lesion, which allosterically switches on a catalytic domain that consumes nicotinamide adenine dinucleotide (NAD⁺) to build branched poly(ADP-ribose) chains on PARP1 itself and on nearby chromatin proteins. Those chains are a transient recruitment signal, drawing XRCC1 and the ligase machinery of base excision and single-strand break repair to the damage; automodification then repels PARP1 from the DNA and releases it, so PARylation is both the summons and the timer. Excessive activation is harmful in its own right — NAD⁺ consumption on this scale depletes the substrate for glycolysis and drains cellular adenosine triphosphate, and the resulting parthanatos pathway of cell death contributes to injury in ischemia and neurodegeneration.

PARP1's clinical importance rests on synthetic lethality with homologous recombination deficiency. In tumors with mutated BRCA1 or BRCA2, the double-strand breaks that arise when replication meets unrepaired single-strand damage cannot be repaired accurately, so those cells die while normal cells survive. The dominant mechanism is not loss of catalytic activity but trapping: a PARP inhibitor holds PARP1 on the DNA it has bound, and the stalled complex is what collapses the oncoming fork, which is why inhibitors are ranked clinically by trapping potency rather than enzymatic potency. This principle underpins the approval of olaparib, niraparib, rucaparib and talazoparib across ovarian cancer, breast cancer, pancreatic and prostate Cancers, most often as maintenance after a platinum response. Resistance arises through reversion mutations that restore the repair gene, loss of the trapping-sensitive target, or restoration of fork protection.

Beyond DNA repair, PARP1 regulates transcription, chromatin architecture and inflammatory signaling, and NAD⁺ competition links it to sirtuin activity and mitochondrial function — a set of roles that keeps the enzyme of interest well outside oncology, and that also explains part of the toxicity of blocking it.

Recent Publications Summary

PARP1 (poly(ADP-ribose) polymerase 1) continues to be a major focus in cancer therapeutics due to its critical role in DNA damage repair. Recent studies demonstrate the efficacy of PARP inhibitors across multiple cancer types, including ovarian, breast, prostate, and endometrial Cancers. The clinical approval of PARP1 inhibitors such as olaparib and niraparib has established PARP1 as a validated therapeutic target, particularly in BRCA1/2-deficient tumors where defects in homologous recombination render tumors dependent on PARP1-mediated base excision repair 42092176May. CRISPR screening has further validated PARP1 dependency in BRCA1-/- tumors as a synthetic lethal interaction 41833894Mar.

Recent drug development efforts have focused on next-generation PARP1 inhibitors designed to overcome limitations of first-generation agents. XZ8078, a novel dual-target degrader targeting both PARP1 and IKZF3, demonstrated superior efficacy against HR-proficient and olaparib-resistant cancer cells, with tumor growth inhibition values significantly exceeding those of established agents 42380731Jul. Similarly, JPI-547, a second-generation PARP inhibitor that targets PARP1/2 and tankyrase, showed potent antitumor activity in olaparib-resistant BRCA1/2-mutant models by suppressing RAD51-mediated homologous recombination restoration 42092176May. Additional strategies include dual PARP1/CDK6 inhibitors (PC8) for triple-negative breast cancer, which modulate Wnt signaling and exhibit improved metabolic stability 41795344Mar, and dual EGFR/PARP-1 inhibitors achieving IC50 values of 0.36 μM against PARP-1 in enzymatic assays while inducing apoptosis and cell-cycle arrest 42207930May.

Combination therapies leveraging PARP1 inhibition show enhanced therapeutic efficacy across multiple treatment modalities. TopBP1 inhibition via CS18 synergizes with PARP inhibitors across multiple cancer types and enhances osimertinib sensitivity in EGFR-mutated NSCLC cells 42555732Aug. The combination of PARP inhibition with T-cell receptor β-chain-directed antibody fusion molecules promotes polyclonal antitumor immunity in metastatic castration-resistant prostate cancer 42386344Jul. olaparib combined with radium-223, an α-emitting radiopharmaceutical, leverages preclinical evidence of synergy between PARP inhibition and radiation therapy 42096662May. In endometriosis, the progesterone receptor modulator RU486 combined with olaparib reactivates p53-dependent apoptosis by targeting both hormonal signaling and PARP1-mediated DNA repair 41707660Feb.

Emerging therapeutic approaches have expanded PARP1 targeting beyond traditional small-molecule inhibitors. Genetic circuit-driven systemic delivery of PARP1-specific siRNA assembled into small extracellular vesicles achieved significant PARP1 gene silencing within breast tumors and potent tumor growth inhibition in BRCA2-deficient models 42097228May. Radiolabeled PARP inhibitors, including [211At]talazoparib, enable both targeted alpha-particle therapy and noninvasive imaging of PARP1 expression 42257398Jun. BBB-crossing olaparib-cyanine dye conjugates improve potency for glioblastoma treatment by enhancing cellular uptake while maintaining PARP1 inhibitory activity 42035252Apr. Pt(II)-based targeted drug conjugates demonstrated higher tumor growth inhibitory efficacy than olaparib monotherapy in ovarian cancer xenografts with reduced systemic toxicity 41996568Apr. Natural product-derived inhibitors, such as site-specifically modified apigeninidin derivatives and homoisoflavanone compounds that induce parthanatos-like cell death, represent additional avenues for PARP1-directed therapy 41653678Feb41603109Jan.

Mechanistic and analytical advances support continued PARP1 drug development. Fragment-based design coupled with artificial intelligence and machine learning identified novel PARP-1 inhibitors with favorable ADME properties and predicted anti-cancer potential against triple-negative breast cancer 41724073Feb. Computational free-energy calculations, including absolute binding free energy (ABFE) methods, accurately recapitulate PARP1 selectivity versus PARP2 across clinically relevant inhibitors 41999312Apr. Beyond cancer, PARP1 modulation addresses non-malignant diseases: compounds elevating NAD+ levels downregulate PARP1 protein expression and restore mitochondrial complex function in Parkinson's disease models 42247013Jun, while prostaglandin D2 suppresses PARP1 to enhance mitochondrial quality control and ovarian competence 42176571May. Cell Lysate Fluorescence Anisotropy (CFAST) provides rapid detection of cellular PARP1 protein levels and inhibitor binding in a dose-dependent manner 42439473Jul, and validated analytical methods including stability-indicating HPLC ensure pharmaceutical quality control of PARP inhibitors 42304726Jun.

What Changes, What Holds

1. Prostate Cancers harbor PARP1 dependency when HR pathways are defective
REINFORCES CRISPR screening validates the synthetic lethal interaction between HR loss and PARP1 dependence in BRCA1-deficient tumors 41833894Mar. Prostate joins breast, ovarian, and endometrial Cancers as responsive to PARP inhibition through the same HR-deficiency mechanism the overview establishes; the principle extends rather than changes.

2. Next-generation PARP1 degraders overcome olaparib resistance in HR-proficient and refractory tumors
NEW DIRECTION XZ8078, JPI-547, and dual PARP1/CDK6 inhibitors circumvent first-generation resistance by targeting PARP1 alongside IKZF3, tankyrase, or cell-cycle regulators 42380731Jul42092176May. The overview presents approved PARPis as established therapeutics but does not address acquired resistance or strategies being developed to overcome it, a clinical frontier the baseline does not contemplate.

3. Combination PARP1 inhibition with TopBP1 targeting or immunotherapy enhances efficacy beyond monotherapy
NEW DIRECTION TopBP1 inhibition, T-cell antibodies, radium-223, and RU486 each synergize with PARPis across cancer and endometriosis contexts 42555732Aug42386344Jul. The overview frames PARP1 inhibition around synthetic lethality but does not discuss complementary pathway targeting or how combining PARP1 inhibition with immune or hormonal strategies amplifies therapeutic benefit.

4. Radiolabeled, blood-brain-barrier-crossing, and vesicle-delivered PARP1 inhibitors expand beyond small-molecule monotherapy
NEW DIRECTION Radiolabeled talazoparib, olaparib-cyanine conjugates, and PARP1-siRNA carried in extracellular vesicles accomplish imaging, CNS penetration, and gene silencing 42257398Jun42035252Apr. The overview describes approved small-molecule PARPis for systemic administration; it does not cover radiopharmaceutical engineering, blood-brain penetrance, or RNA-based silencing as modalities for PARP1 targeting.

5. PARP1 inhibition improves mitochondrial function in Parkinson's disease independent of DNA repair
NEW DIRECTION NAD+-elevating compounds and prostaglandin D2 suppress PARP1 expression to restore mitochondrial complex I activity and ovarian oocyte competence 42247013Jun42176571May. The overview limits PARP1's therapeutic relevance to DNA damage and cancer; these findings establish non-oncologic roles where PARP1 modulation addresses neurodegeneration and reproductive pathology through mitochondrial rather than genotoxic mechanisms.

Overview update candidates: 2.